Clinical practice pathways for evaluation and medication choice for attention-deficit/hyperactivity disorder symptoms in autism spectrum disorders

Pediatrics

Volumn 130, Issue SUPPL. 2, 2012, Pages

  Mahajan, Rajneesh ^a   Bernal, Maria Pilar ^b   Panzer, Rebecca ^c   Whitaker, Agnes ^d   Roberts, Wendy ^e   Handen, Benjamin ^f   Hardan, Antonio ^g   Anagnostou, Evdokia ^h   Veenstra Vander Weele, Jeremy ⁱ  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Kaiser Permanente Northern California ^*  (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^e HOSPITAL FOR SICK CHILDREN   (Canada)

^f UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^g STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF TORONTO   (Canada)

ⁱ VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ADHD symptoms; Autism spectrum disorders; Hyperactivity; Impulsivity; Inattention

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; AMPHETAMINE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATOMOXETINE; CENTRAL STIMULANT AGENT; CLONIDINE; DEXAMPHETAMINE; DEXMETHYLPHENIDATE; GUANFACINE; LISDEXAMFETAMINE; METHYLPHENIDATE; NEUROLEPTIC AGENT; NORTRIPTYLINE; PENTOXIFYLLINE; PLACEBO; RISPERIDONE; TIANEPTINE; TOPIRAMATE;

ARTICLE; ATTENTION DEFICIT DISORDER; AUTISM; AUTISM TREATMENT NETWORK; CHILD; CHILD BEHAVIOR; CLINICAL PRACTICE; COGNITIVE DEFECT; COMORBIDITY; CONSENSUS; DRUG DOSE TITRATION; HEALTH CARE PERSONNEL; HUMAN; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; QUALITY OF LIFE; REGISTER; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; CRITICAL PATHWAYS; FEMALE; HUMANS; MALE;

EID: 84868619228     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2012-0900J     Document Type: Article

References (66)

1. Bauman ML. Medical comorbidities in autism: challenges to diagnosis and treatment. Neurotherapeutics. 2010;7(3):320-327
2. Jeste SS. The neurology of autism spectrum disorders. Curr Opin Neurol. 2011;24 (2):132-139
3. Levy SE, Giarelli E, Lee LC, et al. Autism spectrum disorder and co-occurring developmental, psychiatric, and medical conditions among children in multiple populations of the United States. J Dev Behav Pediatr. 2010; 31(4):267-275
4. Gillberg C, Billstedt E. Autism and Asperger syndrome: coexistence with other clinical disorders. Acta Psychiatr Scand . 2000;102 (5):321-330
5. First MB. Mutually exclusive versus co-occurring diagnostic categories: the challenge of diagnostic comorbidity. Psychopathology. 2005;38(4):206-210 (Pubitemid 41254169)
6. Matson JL, Nebel-Schwalm MS. Comorbid psychopathology with autism spectrum disorder in children: an overview. Res Dev Disabil. 2007;28(4):341-352 (Pubitemid 46810191)
7. Simonoff E, Pickles A, Charman T, Chandler S, Loucas T, Baird G. Psychiatric disorders in children with autism spectrum disorders: prevalence, comorbidity, and associated factors in a population-derived sample. J Am Acad Child Adolesc Psychiatry. 2008;47(8):921-929
8. Joshi G, Petty C, Wozniak J, et al. The heavy burden of psychiatric comorbidity in youth with autism spectrum disorders: a large comparative study of a psychiatrically referred population. J Autism Dev Disord. 2010;40(11):1361-1370
9. Gjevik E, Eldevik S, Fjæran-Granum T, Sponheim E. Kiddie-SADS reveals high rates of DSM-IV disorders in children and adolescents with autism spectrum disorders. J Autism Dev Disord . 2011;41(6): 761-769
10. Gadow KD, DeVincent CJ, Pomeroy J, Azizian A. Psychiatric symptoms in preschool children with PDD and clinic and comparison samples. J Autism Dev Disord. 2004;34(4):379-393 (Pubitemid 39127714)
11. Murray MJ. Attention-deficit/hyperactivity disorder in the context of autism spectrum disorders. Curr Psychiatry Rep. 2010; 12(5):382-388
12. Arnold LE, Vitiello B, McDougle C, et al. Parent-defined target symptoms respond to risperidone in RUPP autism study: customer approach to clinical trials. J Am Acad Child Adolesc Psychiatry. 2003;42(12): 1443-1450 (Pubitemid 39585974)
13. Clark T, Feehan C, Tinline C, Vostanis P. Autistic symptoms in children with attention deficit-hyperactivity disorder. Eur Child Adolesc Psychiatry. 1999;8(1):50-55 (Pubitemid 29222751)
14. Reiersen AM, Constantino JN, Volk HE, Todd RD. Autistic traits in a population-based ADHD twin sample. J Child Psychol Psychiatry. 2007;48(5):464-472 (Pubitemid 46901223)
15. Yoshida Y, Uchiyama T. The clinical necessity for assessing attention deficit/hyperactivity disorder (AD/HD) symptoms in children with high-functioning pervasive developmental disorder (PDD). Eur Child Adolesc Psychiatry. 2004;13(5):307-314 (Pubitemid 39390322)
16. Reiersen AM, Constantino JN, Todd RD. Co-occurrence of motor problems and autistic symptoms in attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2008;47(6):662-672
17. American Psychiatric Association. Diagnostic and Statistical Manual of Medical Disorders, Revised 4th ed. Washington, DC: American Psychiatric Association; 2000
18. Castellanos FX. DSM-5 ADHD and disruptive behavior disorders work group. American Psychiatric Association DSM-5 development. Available at: www.dsm5.org/progress reports/pages/0904dsm-vadhdanddisruptive behaviordisordersworkgroup.aspx. Accessed August 5, 2011
19. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. A 14-month randomized clinical trial of treatment strategies for attention-deficit/ hyperactivity disorder. Arch Gen Psychiatry. 1999;56(12):1073-1086
20. Pliszka S; AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-de ficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(7):894-921
21. American Academy of Pediatrics. Clinical practice guideline: diagnosis and evaluation of the child with attention-deficit/ hyperactivity disorder. Pediatrics. 2000;105 (5):1158-1170
22. American Academy of Pediatrics. Subcommittee on Attention-Deficit/ Hyperactivity Disorder and Committee on Quality Improvement. Clinical practice guideline: treatment of the school-aged child with attention-deficit/ hyperactivity disorder. Pediatrics. 2001;108(4):1033-1044
23. Guyatt GH, Oxman AD, Vist GE, et al GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008; 336(7650):924-926 (Pubitemid 351632017)
24. Ghuman JK, Aman MG, Lecavalier L, et al. Randomized, placebo-controlled, crossover study of methylphenidate for attentiondeficit/ hyperactivity disorder symptoms in preschoolers with developmental disorders. J Child Adolesc Psychopharmacol. 2009;19(4):329-339
25. Subcommittee on Attention-Deficit/Hyperactivity Disorder; Steering Committee on Quality Improvement and Management, Wolraich M, Brown L, Brown RT, et al. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-de ficit/hyperactivity disorder in children and adolescents. Pediatrics. 2011; 128(5):1007-1022
26. Filipek PA, Accardo PJ, Ashwal S, et al. Practice parameter: screening and diagnosis of autism: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Child Neurology Society. Neurology. 2000;55(4):468-479 (Pubitemid 30647241)
27. Johnson CP, Myers SM; American Academy of Pediatrics Council on Children With Disabilities. Identification and evaluation of children with autism spectrum disorders. Pediatrics. 2007;120(5):1183-1215 (Pubitemid 350085561)
28. Conners CK, Sitarenios G, Parker JD, Epstein JN. The revised Conners' Parent Rating Scale (CPRS-R): factor structure, reliability, and criterion validity. J Abnorm Child Psychol. 1998;26(4):257-268 (Pubitemid 28359774)
29. Wolraich ML, Feurer ID, Hannah JN, Baumgaertel A, Pinnock TY. Obtaining systematic teacher reports of disruptive behavior disorders utilizing DSM-IV. J Abnorm Child Psychol. 1998;26(2):141-152 (Pubitemid 28249061)
30. Wolraich ML, Lambert W, Doffing MA, Bickman L, Simmons T, Worley K. Psychometric properties of the Vanderbilt ADHD diagnostic parent rating scale in a referred population. J Pediatr Psychol. 2003;28(8): 559-567 (Pubitemid 37449138)
31. Wilens TE. Mechanism of action of agents used in attention-deficit/ hyperactivity disorder. J Clin Psychiatry. 2006;67(suppl 8): 32-38
32. Posey DJ, Aman MG, Arnold LE, et al Research Units on Pediatric Psychopharmacology Autism Network. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Arch Gen Psychiatry. 2005;62(11):1266-1274 (Pubitemid 41586926)
33. Brookman-Frazee L, Stahmer A, Baker- Ericzén MJ, Tsai K. Parenting interventions for children with autism spectrum and disruptive behavior disorders: opportunities for cross-fertilization. Clin Child Fam Psychol Rev. 2006;9(3-4):181-200 (Pubitemid 44914815)
34. Arnold LE, Aman MG, Cook AM, et al. Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial. J Am Acad Child Adolesc Psychiatry. 2006;45(10):1196-1205 (Pubitemid 44465640)
35. Geller D, Donnelly C, Lopez F, et al. Atomoxetine treatment for pediatric patients with attention-deficit/hyperactivity disorder with comorbid anxiety disorder. J Am Acad Child Adolesc Psychiatry. 2007; 46(9):1119-1127 (Pubitemid 47295923)
36. Aman MG, Lam KS, Collier-Crespin A. Prevalence and patterns of use of psychoactive medicines among individuals with autism in the Autism Society of Ohio. J Autism Dev Disord. 2003;33(5):527-534 (Pubitemid 37351601)
37. Siegel M, Beaulieu AA. Psychotropic medications in children with autism spectrum disorders: a systematic review and synthesis for evidence-based practice. J Autism Dev Disord. 2011;42(8):1592-1605
38. Handen BL, Sahl R, Hardan AY. Guanfacine in children with autism and/or intellectual disabilities. J Dev Behav Pediatr. 2008;29(4): 303-308
39. McCracken JT, McGough J, Shah B, et al Research Units on Pediatric Psychopharmacology Autism Network. Risperidone in children with autism and serious behavioral problems. N Engl J Med. 2002;347(5): 314-321 (Pubitemid 34815353)
40. Owen R, Sikich L, Marcus RN, et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics. 2009;124(6):1533-1540
41. Handen BL, Johnson CR, Lubetsky M. Efficacy of methylphenidate among children with autism and symptoms of attentiondeficit hyperactivity disorder. J Autism Dev Disord. 2000;30(3):245-255
42. Aman MG, Hollway JA, McDougle CJ, et al. Cognitive effects of risperidone in children with autism and irritable behavior. J Child Adolesc Psychopharmacol . 2008;18(3):227-236
43. Troost PW, Lahuis BE, Steenhuis MP, et al. Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study. J Am Acad Child Adolesc Psychiatry. 2005;44(11):1137-1144 (Pubitemid 41508125)
44. Shea S, Turgay A, Carroll A, et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics. 2004;114(5). Available at: www.pediatrics.org/cgi/content/full/114/5/e634
45. Nagaraj R, Singhi P, Malhi P. Risperidone in children with autism: randomized, placebocontrolled, double-blind study. J Child Neurol. 2006;21(6):450-455 (Pubitemid 44069792)
46. Marcus RN, Owen R, Kamen L, et al. A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry. 2009;48(11):1110-1119
47. Akhondzadeh S, Fallah J, Mohammadi MR, et al. Double-blind placebo-controlled trial of pentoxifylline added to risperidone: effects on aberrant behavior in children with autism. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(1):32-36
48. Rezaei V, Mohammadi MR, Ghanizadeh A, et al. Double-blind, placebo-controlled trial of risperidone plus topiramate in children with autistic disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34 (7):1269-1272
49. Niederhofer H, Staffen W, Mair A. Tianeptine: a novel strategy of psychopharmacological treatment of children with autistic disorder. Hum Psychopharmacol. 2003;18(5):389-393 (Pubitemid 36896424)
50. Di Martino A, Melis G, Cianchetti C, Zuddas A. Methylphenidate for pervasive developmental disorders: safety and efficacy of acute single dose test and ongoing therapy: an open-pilot study. J Child Adolesc Psychopharmacol. 2004;14(2):207-218 (Pubitemid 38988787)
51. Santosh PJ, Baird G, Pityaratstian N, Tavare E, Gringras P. Impact of comorbid autism spectrum disorders on stimulant response in children with attention deficit hyperactivity disorder: a retrospective and prospective effectiveness study. Child Care Health Dev. 2006;32(5):575-583 (Pubitemid 44210096)
52. Posey DJ, Wiegand RE, Wilkerson J, Maynard M, Stigler KA, McDougle CJ. Open-label atomoxetine for attention-deficit/ hyperactivity disorder symptoms associated with high-functioning pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2006;16(5):599-610 (Pubitemid 44739916)
53. Zeiner P, Gjevik E, Weidle B. Response to atomoxetine in boys with high-functioning autism spectrum disorders and attention deficit/hyperactivity disorder. Acta Paediatr. 2011;100(9):1258-1261
54. Scahill L, Aman MG, McDougle CJ, et al. A prospective open trial of guanfacine in children with pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2006;16(5):589-598 (Pubitemid 44737213)
55. Ming X, Gordon E, Kang N, Wagner GC. Use of clonidine in children with autism spectrum disorders. Brain Dev. 2008;30(7):454-460
56. Aman MG, McDougle CJ, Scahill L, et al. Medication and parent training in children with pervasive developmental disorders and serious behavior problems: results from a randomized clinical trial [published correction appears in J Am Acad Child Adolesc Psychiatry. 2010;49(7):727]. J Am Acad Child Adolesc Psychiatry. 2009;48(12): 1143-1154.
57. Malone RP, Maislin G, Choudhury MS, Gifford C, Delaney MA. Risperidone treatment in children and adolescents with autism: short- and long-term safety and effectiveness. J Am Acad Child Adolesc Psychiatry. 2002 Feb; 41(2):140-147 (Pubitemid 38338162)
58. Masi G, Cosenza A, Mucci M, Brovedani P. Open trial of risperidone in 24 young children with pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry. 2001;40(10):1206-1214 (Pubitemid 32917087)
59. Research Units on Pediatric Psychopharmacology Autism Network. Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months. Am J Psychiatry. 2005;162(7): 1361-1369
60. Gagliano A, Germanò E, Pustorino G, et al. Risperidone treatment of children with autistic disorder: effectiveness, tolerability, and pharmacokinetic implications. J Child Adolesc Psychopharmacol. 2004;14(1):39-47 (Pubitemid 38525952)
61. Kim Y, Cho SC, Shin MS, Kim JW, Lee SH, Kim BN. Retrospective case series of aripiprazole augmentation in pervasive developmental disorders. Psychiatry Investig. 2010;7(3):220-223
62. Kemner C, Willemsen-Swinkels SH, de Jonge M, Tuynman-Qua H, van Engeland H. Open-label study of olanzapine in children with pervasive developmental disorder. J Clin Psychopharmacol. 2002;22(5):455-460
63. Malone RP, Delaney MA, Hyman SB, Cater JR. Ziprasidone in adolescents with autism: an open-label pilot study. J Child Adolesc Psychopharmacol. 2007;17(6):779-790 (Pubitemid 351158593)
64. Fido A, Al-Saad S. Olanzapine in the treatment of behavioral problems associated with autism: an open-label trial in Kuwait. Med Princ Pract. 2008;17(5):415-418
65. Erickson CA, Posey DJ, Stigler KA, Mullett J, Katschke AR, McDougle CJ. A retrospective study of memantine in children and adolescents with pervasive developmental disorders. Psychopharmacology (Berl). 2007;191(1):141-147 (Pubitemid 46294942)
66. Rugino TA, Samsock TC. Levetiracetam in autistic children: an open-label study. J Dev Behav Pediatr. 2002;23(4):225-230 (Pubitemid 34947180)